Uterine Fibroids & Fertility
Not all fibroids affect fertility equally — location matters more than size, and targeted treatment can restore reproductive potential in most women.
Affect up to 70–80% of women by age 50; fertility-impairing fibroids present in 5–10% of infertile women
How Uterine Fibroids Affects Fertility
The impact of uterine fibroids on fertility depends primarily on their location and size, not their mere presence. Submucosal fibroids (FIGO type 0, 1, and 2 — projecting into or distorting the uterine cavity) have the greatest detrimental effect. They impair fertility through multiple mechanisms: mechanical obstruction of the tubal ostia, disruption of normal sperm transport, alteration of normal uterine contractility, impairment of implantation through altered endometrial vascularity and molecular signaling (reduced HOXA10 and LIF expression), and increased early pregnancy loss. A systematic review by Pritts et al. (Fertil Steril 2009) found that submucosal fibroids reduced implantation rates by 50–60% and live birth rates by approximately 70% — a clinically dramatic effect that is largely reversible with myomectomy.
Intramural fibroids (FIGO type 3–5, within the myometrium without cavity distortion) have a more variable and debated impact. Current evidence, including a meta-analysis by Somigliana et al. (Hum Reprod Update 2016), suggests that intramural fibroids ≥ 4 cm are associated with significantly reduced implantation and live birth rates in IVF, even without overt cavity distortion on 2D ultrasound. Proposed mechanisms include altered uterine peristalsis, reduced subendometrial vascularity, and mechanical pressure effects. For smaller intramural fibroids (< 4 cm) not abutting the cavity, current evidence does not support routine myomectomy before IVF, and the surgical risks may outweigh uncertain benefits. This remains an area of active clinical debate.
Subserosal fibroids (FIGO type 6–7, projecting outward from the uterus) have minimal impact on intrauterine fertility unless very large and compressing the fallopian tubes externally. They are rarely treated for reproductive purposes. Pedunculated subserosal fibroids occasionally undergo torsion and may be removed laparoscopically for symptomatic reasons. When multiple fibroid types coexist — a common finding — the clinical decision centers on the most impactful lesion, typically the submucosal or large intramural fibroid. MRI is the gold-standard imaging modality for fibroid mapping, providing superior characterization of fibroid number, location, size, and relationship to the endometrial cavity compared to ultrasound.
Treatment Options
Treatment is individualized based on age, severity, duration of infertility, and partner factors. Work with your reproductive endocrinologist to determine the right sequence for your specific situation.
Hysteroscopic Myomectomy (Submucosal Fibroids)
Hysteroscopic resection of submucosal fibroids (FIGO type 0 and 1; partially submucosal type 2) is the definitive, minimally invasive treatment for cavity-distorting fibroids. Performed through the cervix without abdominal incision, it carries minimal recovery time and surgical risk. Post-operative pregnancy rates improve significantly: Pritts et al. (2009) found live birth rates of 52% versus 25% (untreated) in matched comparisons. All submucosal fibroids identified before IVF should be removed hysteroscopically. Recovery is typically complete within 4–6 weeks; a hysteroscopic evaluation at 6–8 weeks confirms complete resection and normal cavity.
Typical success rate
Live birth rate approximately doubled vs. untreated submucosal fibroids (Pritts et al., 2009)
Laparoscopic or Open Myomectomy (Intramural/Subserosal Fibroids)
Laparoscopic myomectomy (for fibroids < 8–10 cm, fewer than 4–5 in number) or open (laparotomic) myomectomy removes intramural and subserosal fibroids through abdominal incisions. Laparoscopic myomectomy is preferred at experienced centers for appropriately sized fibroids, offering shorter recovery and equivalent outcomes. Open myomectomy is reserved for large, numerous, or deeply intramural fibroids requiring extensive uterine reconstruction. Post-myomectomy, cesarean delivery is recommended to prevent uterine rupture if the uterine cavity was entered. A 3–6 month healing interval before IVF is typically required.
Typical success rate
Improved IVF and spontaneous pregnancy outcomes; cumulative live birth rates of 50–60% within 18 months
GnRH Agonist Pre-treatment for Fibroid Shrinkage
A 3–6 month course of GnRH agonist (e.g., leuprolide acetate) before myomectomy reduces fibroid volume by 30–50% through estrogen suppression, reduces intraoperative blood loss, and may convert an open myomectomy to a laparoscopic approach. It can also reduce anemia from heavy uterine bleeding before surgery. However, GnRH agonists cause fibroid softening that can make surgical planes less distinct, and fibroids regrow after discontinuation. Pre-operative GnRH agonist use is recommended for large or vascular fibroids to reduce surgical complexity and risk.
IVF with Careful Fibroid Assessment
Women with intramural fibroids < 4 cm not distorting the cavity can proceed with IVF without prior myomectomy, as current evidence does not demonstrate a consistent benefit of surgery in this group. Careful pre-IVF assessment with saline sonohysterogram or MRI is essential to confirm cavity integrity. If fibroids grow or cavity distortion becomes evident, myomectomy should be reconsidered. All submucosal fibroids must be removed before IVF — this is not optional.
Typical success rate
35–45% live birth per transfer for intramural fibroids not distorting cavity; lower if cavity affected
Uterine Fibroid Embolization (UFE)
UFE (uterine artery embolization) is a radiological procedure that blocks blood supply to fibroids, causing them to shrink. While effective for symptom control, UFE is generally not recommended for women desiring future fertility due to the risk of inadvertent embolization of uterine or ovarian arteries, which may reduce ovarian reserve and endometrial vascularity. ASRM advises that women planning pregnancy should not undergo UFE and should opt for myomectomy instead.
What Patients with Uterine Fibroids Can Expect
The fertility impact of fibroids is highly location-dependent. Submucosal fibroids have the most dramatic and reversible effect — hysteroscopic removal essentially normalizes IVF outcomes. Intramural fibroids have a moderate, size-dependent effect. Subserosal fibroids have minimal impact. Post-myomectomy, spontaneous and IVF-assisted pregnancy rates are significantly improved, though fibroid recurrence (at 5 years, 50–60% of patients have ultrasound-detectable recurrence) may require repeat evaluation before future pregnancies.
| Treatment | Typical Success Range |
|---|---|
| IVF with submucosal fibroid (untreated) | Implantation rate reduced 50–70%; live birth rate ~25% |
| IVF after hysteroscopic myomectomy (submucosal) | Live birth rate ~52%; implantation normalized |
| IVF with intramural fibroid ≥ 4 cm (no cavity distortion) | 25–35% live birth per transfer |
| IVF with intramural fibroid < 4 cm (no cavity distortion) | 35–45% live birth per transfer |
| Spontaneous conception after myomectomy (intramural/subserosal) | 50–60% cumulative at 18 months |
Individual outcomes vary significantly based on age, ovarian reserve, partner factors, and clinic expertise. These figures are based on published research (ASRM, SART, Cochrane Reviews) and national averages — they are not guarantees. Ask your clinic for their own reported outcomes for your specific diagnosis and age group.
Questions to Ask Your Reproductive Endocrinologist
Bring this list to your first consultation to make the most of your appointment.
- 1
What type of fibroid do I have — submucosal, intramural, or subserosal — and does it distort my uterine cavity?
- 2
Has my uterine cavity been evaluated by saline sonohysterogram or MRI rather than standard ultrasound alone?
- 3
Do you recommend removing my fibroid before IVF, and what is the evidence specific to my fibroid type and size?
- 4
What surgical approach do you recommend — hysteroscopic, laparoscopic, or open — and what is your experience with this?
- 5
If I have a myomectomy, when can I start IVF, and will I need a cesarean delivery?
- 6
What is the fibroid recurrence rate, and how will we monitor for new fibroids before a second pregnancy?
When to See a Specialist
Women with known uterine fibroids who are planning pregnancy should see a reproductive endocrinologist for fibroid mapping (ideally with MRI or saline sonohysterogram) before trying to conceive. Any woman diagnosed with a submucosal fibroid should see a specialist promptly — this is a surgically correctable cause of infertility that significantly reduces IVF success if left in place.
Ready to Find a Clinic That Specializes in Uterine Fibroids?
Look for clinics with reproductive endocrinologists (REs) who have documented experience treating Uterine Fibroids. Ask about their specific outcomes for your diagnosis and age group during your first consultation — outcomes vary significantly by clinic.
Select your state to browse fertility clinics near you:
Related Articles
Beta hCG After IVF: What Your First Result Means
Your first beta hCG result after IVF is one of the most nerve-wracking numbers in the entire process. This guide explains what it means, what doubling times to expect, how to interpret a borderline result, and what comes next.
OHSS After IVF: Symptoms, Classification, Prevention & Treatment
Ovarian hyperstimulation syndrome is the most serious complication of IVF stimulation. This guide covers who is at risk, how severity is graded, evidence-based prevention strategies, and what to do if symptoms develop.
ICI vs IUI vs IVF: Which Treatment Should You Start With?
The right starting point for fertility treatment is never the same for everyone — it depends entirely on your diagnosis. This guide gives you a clear, evidence-based framework for deciding between ICI, IUI, and IVF.
Related Conditions
Endometriosis
Affects ~10% of reproductive-age women; up to 50% of infertile women
Learn moreUnexplained Infertility
Diagnosed in 15–30% of infertile couples after standard evaluation
Learn moreRecurrent Pregnancy Loss (RPL)
Affects 1–2% of couples; recurrence risk rises sharply after 3 or more losses
Learn moreAdenomyosis
Estimated in 20–35% of reproductive-age women; present in up to 40% of infertile women evaluated by MRI
Learn more